OneSource Specialty Pharma Ltd
OneSource Specialty Pharma Q4 FY26 earnings call: Revenue & Margins
Q4 FY26 earnings call: what management guided on revenue, margins and order book.
The short version
OneSource expects strong growth in FY27 and FY28, with meaningful revenue contributions starting FY27 and commercial biologics manufacturing beginning FY29. OneSource expects meaningful contribution from biologics business starting FY27 and FY28, with commercial manufacturing set to begin post-FY28, likely FY29 onwards.
From OneSource Specialty Pharma Ltd's Q4 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- OneSource expects strong growth in FY27 and FY28, with meaningful revenue contributions starting FY27 and commercial biologics manufacturing beginning FY29.
- The company reiterated its FY28 guidance of US$400 million revenue and 40% EBITDA margin.
- Expansion of injectable and soft gel capacities, including three DDC lines by end of FY27, will drive sequential quarter-on-quarter revenue and EBITDA improvement.
- Demand-supply gap expected to persist for at least the next 2 years, with high customer demand and capacity reservations from clients.
- Biologics business shows strong funnel with agreements expected in FY27 and meaningful contributions in FY28, indicating a long runway for growth.
2 more points from OneSource Specialty Pharma Ltd's call on revenue
Pro opens every point from 15K+ earnings calls
Profitability & Margins
See what OneSource Specialty Pharma Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- The company is heavily investing in capacity expansion, particularly in the injectable (DDC) and soft gelatine segments to support future growth.
- A fourth injectable line is being introduced in Unit 2, featuring advanced capabilities like handling high viscosity pre-filled syringes.
- Two additional injectable lines are planned for installation within the year, with three lines expected to be operational by end of FY27.
- Capacity expansion also includes upgrading batch sizes from 200 liters to up to 750–1,000 liters, increasing output by 2.5x.
- The capex for these expansions is fully funded through incremental domestic and international borrowings.
2 more points from OneSource Specialty Pharma Ltd's call on capex
Pro opens every point from 15K+ earnings calls
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what OneSource Specialty Pharma Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- The company is fully committed to its current capacity, with strong visibility of robust demand across markets where approvals exist or are expected.
- Customers have secured capacity reservations through upfront fees and take-or-pay contracts, indicating a firm orderbook on capacity.
- Demand-supply gap expected to persist for at least the next two years, reflecting strong pending orders and order pipeline.
- New manufacturing lines (two additional lines scheduled this year and another next year) are being added to meet this demand.
- Capacity expansions underway in commercial manufacturing, particularly injectable lines, expected to start contributing beyond FY28.
2 more points from OneSource Specialty Pharma Ltd's call on order book
Pro opens every point from 15K+ earnings calls
OneSource Specialty Pharma Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest (Q4 FY26): revenue ₹428 Cr, net profit ₹5 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What OneSource Speci.'s management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Balaxi Pharma (Q4 FY26)
Q4 FY26 consolidated revenue: ₹70.71 crore, down 7.3% YoY from ₹76.27 crore in Q4 FY25 (Page 22). Key investor presentation takeaways from Balaxi Pharma's Q4 FY
- Accretion Pha. (Q4 FY26)
45.89 crore, up 18.24% YoY (Page 28). Key investor presentation takeaways from Accretion Pharmaceuticals Ltd's Q4 FY26 investor presentation — and how it ranks
- Gujarat Themis Biosyn Ltd (Q4 FY26)
. Key investor presentation takeaways from Gujarat Themis Biosyn Ltd's Q4 FY26 investor presentation — and how it ranks against sector peers.
- Aptus Pharma (Q4 FY26)
The investor presentation reports quarterly revenue of ₹40.36 crore for Q4 FY2026. Key concall takeaways from Aptus Pharma Ltd's Q4 FY26 earnings call — and…
Arthneeti Pro · Annual
OneSource Specialty Pharma Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were OneSource Specialty Pharma Ltd Q4 FY26 results?
OneSource expects strong growth in FY27 and FY28, with meaningful revenue contributions starting FY27 and commercial biologics manufacturing beginning FY29. OneSource expects meaningful contribution from biologics business starting FY27 and FY28, with commercial manufacturing set to begin post-FY28, likely FY29 onwards.
What is OneSource Specialty Pharma Ltd share price analysis?
OneSource Specialty Pharma Ltd currently shows a neutral. The stock trades at a P/E of N/A with a market cap of ₹17,817 Cr. Investors should review the full earnings analysis for detailed insights.
Is OneSource Specialty Pharma Ltd planning capital expenditure?
The company is heavily investing in capacity expansion, particularly in the injectable (DDC) and soft gelatine segments to support future growth.
Keep OneSource Specialty Pharma Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.